Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rifkin

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
American Journal of Ophthalmology|January 4, 2026
Dazdotuftide: Novel Treatment for Non-Infectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical TrialDavid S Chu, Edmund Tsui, Lana M Rifkin, et al.
American Journal of Hematology|July 18, 2018
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignanciesMichael R Savona, Kathryn Kolibaba, Paul Conkling, et al.
Blood Cancer Journal|September 19, 2023
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma managementRobert M Rifkin, Saulius K Girnius, Stephen J Noga, et al.
Investigative Ophthalmology & Visual Science|September 7, 2016
Choroidal Findings in Eyes With Birdshot Chorioretinitis Using Enhanced-Depth Optical Coherence TomographyChristian Böni, Jennifer E Thorne, Richard F Spaide, et al.
Investigative Ophthalmology & Visual Science|August 12, 2017
Fundus Autofluorescence Findings in Eyes With Birdshot ChorioretinitisChristian Böni, Jennifer E Thorne, Richard F Spaide, et al.
British Journal of Haematology|March 5, 2019
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA studyHabte Yimer, Jason Melear, Edward Faber, et al.
Future Oncology (London, England)|October 9, 2023
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myelomaRobert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, et al.
Leukemia & Lymphoma|June 22, 2022
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA studyHabte Yimer, Jason Melear, Edward Faber, et al.
Leukemia & Lymphoma|May 26, 1999
Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow autotransplants in newly diagnosed multiple myelomaR P Gale, R E Park, R W Dubois, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2018
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)Sundar Jagannath, Rafat Abonour, Brian G M Durie, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
American Journal of Ophthalmology|January 4, 2026
Dazdotuftide: Novel Treatment for Non-Infectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical TrialDavid S Chu, Edmund Tsui, Lana M Rifkin, et al.
American Journal of Hematology|July 18, 2018
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignanciesMichael R Savona, Kathryn Kolibaba, Paul Conkling, et al.
Blood Cancer Journal|September 19, 2023
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma managementRobert M Rifkin, Saulius K Girnius, Stephen J Noga, et al.
Investigative Ophthalmology & Visual Science|September 7, 2016
Choroidal Findings in Eyes With Birdshot Chorioretinitis Using Enhanced-Depth Optical Coherence TomographyChristian Böni, Jennifer E Thorne, Richard F Spaide, et al.
Investigative Ophthalmology & Visual Science|August 12, 2017
Fundus Autofluorescence Findings in Eyes With Birdshot ChorioretinitisChristian Böni, Jennifer E Thorne, Richard F Spaide, et al.
British Journal of Haematology|March 5, 2019
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA studyHabte Yimer, Jason Melear, Edward Faber, et al.
Future Oncology (London, England)|October 9, 2023
<i>In</i>-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myelomaRobert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, et al.
Leukemia & Lymphoma|June 22, 2022
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA studyHabte Yimer, Jason Melear, Edward Faber, et al.
Leukemia & Lymphoma|May 26, 1999
Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow autotransplants in newly diagnosed multiple myelomaR P Gale, R E Park, R W Dubois, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2018
Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)Sundar Jagannath, Rafat Abonour, Brian G M Durie, et al.
Pageof 9